Archives for C-reactive protein (CRP)

Accidental Fear or Valid reporting? Risk of New IBD Rises for Patients Treated With Etanercept

The Center for Biosimilars today published an article that concluded that there is a fearful risk of being diagnosed with IBD Crohn’s or Colitis for those currently being treated with Etanercept. Respectfully, I believe this study is incomplete and does not tell the full story. Though I don’t currently have access to the full study, just the Wiley Online Library Summary and the Center for Biosimilars article, until Lifestyle and Diet are factored into these studies I believe they do not tell the complete story.  20 years of clinical and cost outcomes from Integrative Medicine* have demonstrated the following results:
Read More

Categories: Abdominal Pain, alopecia, ankylosing spondylitis, Biologics, C-reactive protein (CRP), CalProctetin, Crohn's Disease, DIAGNOSTIC TESTING, Joel's Story, pemphigus, Pharmaceuticals, psoriasis, Recommended Resources, RESEARCH, Resources, Rheumatoid Arthritis, Stool Analysis, SYMPTOMS, TREATMENT, Ulcerative Colitis, and vitiligo.

US FDA approves Stelara for ulcerative colitis

Do you find these articles helpful? Please donate today so we may continue this service so humanity may prosper in a peaceful world with a peaceful microbiome This past October, the U.S. Food and Drug Administration approved ustekinumab (Stelara by Janssen), a human IL-12 and IL-23 antagonist. This is based on data from a phase 3 UNIFI trial, which demonstrated that ustekinumab induced and maintained clinical remission in a significantly greater proportion of adults with moderately to severely active UC compared with placebo. Trial And Study Results Janssen said at the time the UNIFI data was released that at Week
Read More

Categories: Biologics, C-reactive protein (CRP), CalProctetin, Colonoscopy, Crohn's Disease, Nutrition, One Great Gut Collection, Pharmaceuticals, RESEARCH, Resources, STORIES-OF-HOPE, The Crohn's And Colitis Summit, TREATMENT, and Ulcerative Colitis.